Severely ill COVID-19 patients may not benefit from expensive monoclonal antibody treatments, challenging assumptions about therapeutic interventions for hospitalized cases. This finding has significant implications for treatment protocols and healthcare resource allocation during ongoing pandemic management.
The phase 3 DisCoVeRy trial tracked 237 hospitalized adults with confirmed SARS-CoV-2 infections for over 15 months, comparing outcomes between those receiving AZD7442 (tixagevimab-cilgavimab combination) versus placebo. The study encompassed infections from both pre-Omicron variants (58.8% of cases) and Omicron subvariants BA1, BA2, and BA5 (33.2% of cases). Clinical status assessments using a 7-point ordinal scale revealed no statistically significant differences between treatment and control groups at day 15 or any subsequent timepoint. Unexpectedly, participants receiving the monoclonal antibody treatment experienced higher rates of rehospitalization between discharge and day 456 compared to placebo recipients.
This outcome contradicts earlier optimism surrounding monoclonal antibody therapies and highlights the complex dynamics of treating severe COVID-19 cases. Unlike outpatient settings where early intervention may prevent hospitalization, patients already requiring inpatient care may have progressed beyond the therapeutic window for antibody treatments. The higher rehospitalization rates among treated patients warrant investigation into potential immune system interference or other mechanistic factors. These results suggest that monoclonal antibodies like AZD7442 may be most effective as preventive measures rather than treatments for established severe disease, fundamentally reshaping clinical decision-making for hospitalized COVID-19 patients and emphasizing the importance of early intervention strategies.